Paul J Clancy Insider Trading Transactions
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for Paul J Clancy.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of Paul J Clancy. Paul J Clancy is Director in INCYTE CORP ($INCY) and EVP, Chief Financial Officer in ALEXION PHARMACEUTICALS INC ($ALXN) and CFO in BIOGEN INC. ($IDPH) and Executive VP and CFO in BIOGEN INC. ($IDPH) and Director in EXACT SCIENCES CORP ($EXAS) and Director in AGIOS PHARMACEUTICALS INC ($AGIO).
Latest Insider Trading Transactions of Paul J Clancy
1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
---|---|---|---|---|---|---|---|
No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Sentiment: All, AGIO, ALXN, IDPH, EXAS, INCY
Page: 1
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Apr 01 2021 | INCY | INCYTE CORP | Clancy Paul J | Director | Grant | A | 81.27 | 298 | 24,218 | 5,094 | 4.8 K to 5.1 K (+6.21 %) |
Mar 19 2021 | EXAS | EXACT SCIENCES COR ... | Clancy Paul J | Director | Grant | A | 0.00 | 2,929 | 0 | 2,929 | 0 to 2.9 K |
Oct 01 2020 | INCY | INCYTE CORP | Clancy Paul J | Director | Grant | A | 89.74 | 260 | 23,332 | 4,515 | 4.3 K to 4.5 K (+6.11 %) |
Jul 01 2020 | INCY | INCYTE CORP | Clancy Paul J | Director | Grant | A | 103.97 | 229 | 23,809 | 4,255 | 4 K to 4.3 K (+5.69 %) |
Jun 01 2020 | AGIO | AGIOS PHARMACEUTIC ... | Clancy Paul J | Director | Option Exercise | M | 0.00 | 1,878 | 0 | 0 | |
Jun 01 2020 | AGIO | AGIOS PHARMACEUTIC ... | Clancy Paul J | Director | Option Exercise | A | 0.00 | 1,686 | 0 | 1,686 | |
Jun 01 2020 | AGIO | AGIOS PHARMACEUTIC ... | Clancy Paul J | Director | Option Exercise | A | 53.35 | 8,096 | 431,922 | 8,096 | |
Jun 01 2020 | AGIO | AGIOS PHARMACEUTIC ... | Clancy Paul J | Director | Buy | M | 0.00 | 1,878 | 0 | 3,278 | 1.4 K to 3.3 K (+134.14 %) |
May 28 2020 | INCY | INCYTE CORP | Clancy Paul J | Director | Option Exercise | A | 98.68 | 10,514 | 1,037,522 | 10,514 | |
May 28 2020 | INCY | INCYTE CORP | Clancy Paul J | Director | Grant | A | 0.00 | 1,282 | 0 | 4,026 | 2.7 K to 4 K (+46.72 %) |
Apr 02 2020 | INCY | INCYTE CORP | Clancy Paul J | Director | Grant | A | 73.23 | 287 | 21,017 | 2,744 | 2.5 K to 2.7 K (+11.68 %) |
Oct 02 2019 | INCY | INCYTE CORP | Clancy Paul J | Director | Grant | A | 74.23 | 266 | 19,745 | 2,226 | 2 K to 2.2 K (+13.57 %) |
Jul 15 2019 | ALXN | ALEXION PHARMACEUT ... | Clancy Paul J | EVP, Chief Financia ... | Payment of Exercise | F | 124.20 | 5,230 | 649,566 | 90,447 | 95.7 K to 90.4 K (-5.47 %) |
Apr 29 2019 | INCY | INCYTE CORP | Clancy Paul J | Director | Option Exercise | A | 75.03 | 12,472 | 935,774 | 12,472 | |
Apr 29 2019 | INCY | INCYTE CORP | Clancy Paul J | Director | Grant | A | 0.00 | 1,520 | 0 | 1,723 | 203 to 1.7 K (+748.77 %) |
Mar 05 2019 | ALXN | ALEXION PHARMACEUT ... | Clancy Paul J | EVP, Chief Financia ... | Grant | A | 0.00 | 9,428 | 0 | 95,677 | 86.2 K to 95.7 K (+10.93 %) |
Mar 04 2019 | ALXN | ALEXION PHARMACEUT ... | Clancy Paul J | EVP, Chief Financia ... | Payment of Exercise | F | 132.93 | 1,079 | 143,431 | 86,249 | 87.3 K to 86.2 K (-1.24 %) |
Feb 11 2019 | ALXN | ALEXION PHARMACEUT ... | Clancy Paul J | EVP, Chief Financia ... | Payment of Exercise | F | 119.57 | 5,981 | 715,148 | 87,328 | 93.3 K to 87.3 K (-6.41 %) |
Jul 12 2018 | ALXN | ALEXION PHARMACEUT ... | Clancy Paul J | EVP, Chief Financia ... | Sell | S | 131.11 | 5,241 | 687,148 | 93,309 | 98.6 K to 93.3 K (-5.32 %) |
Jun 04 2018 | AGIO | AGIOS PHARMACEUTIC ... | Clancy Paul J | Director | Option Exercise | A | 0.00 | 1,400 | 0 | 1,400 | |
Jun 04 2018 | AGIO | AGIOS PHARMACEUTIC ... | Clancy Paul J | Director | Option Exercise | A | 93.50 | 5,700 | 532,950 | 5,700 | |
May 03 2018 | INCY | INCYTE CORP | Clancy Paul J | Director | Option Exercise | A | 60.85 | 15,000 | 912,750 | 15,000 | |
Feb 08 2018 | ALXN | ALEXION PHARMACEUT ... | Clancy Paul J | EVP, Chief Financia ... | Sell | S | 116.31 | 6,079 | 707,048 | 89,014 | 95.1 K to 89 K (-6.39 %) |
Feb 08 2018 | ALXN | ALEXION PHARMACEUT ... | Clancy Paul J | EVP, Chief Financia ... | Grant | A | 0.00 | 48,228 | 0 | 95,093 | 46.9 K to 95.1 K (+102.91 %) |
Jul 12 2017 | ALXN | ALEXION PHARMACEUT ... | Clancy Paul J | EVP, Chief Financia ... | Option Exercise | A | 123.76 | 29,089 | 3,600,055 | 29,089 | |
Jul 12 2017 | ALXN | ALEXION PHARMACEUT ... | Clancy Paul J | EVP, Chief Financia ... | Grant | A | 0.00 | 46,865 | 0 | 46,865 | 0 to 46.9 K |
Jun 15 2017 | AGIO | AGIOS PHARMACEUTIC ... | Clancy Paul J | Director | Option Exercise | A | 50.73 | 9,000 | 456,570 | 9,000 | |
May 31 2017 | INCY | INCYTE CORP | Clancy Paul J | Director | Option Exercise | A | 134.38 | 15,000 | 2,015,700 | 15,000 | |
Apr 27 2017 | IDPH | BIOGEN INC. | Clancy Paul J | Executive VP and CF ... | Sell | S | 290.00 | 9,892 | 2,868,680 | 10,813 | 20.7 K to 10.8 K (-47.78 %) |
Mar 14 2017 | IDPH | BIOGEN INC. | Clancy Paul J | Executive VP and CF ... | Sell | S | 291.55 | 9,891 | 2,883,721 | 20,705 | 30.6 K to 20.7 K (-32.33 %) |
Mar 02 2017 | IDPH | BIOGEN INC. | Clancy Paul J | Executive VP and CF ... | Option Exercise | M | 0.00 | 2,873 | 0 | 0 | |
Mar 02 2017 | IDPH | BIOGEN INC. | Clancy Paul J | Executive VP and CF ... | Option Exercise | M | 0.00 | 1,152 | 0 | 0 | |
Mar 02 2017 | IDPH | BIOGEN INC. | Clancy Paul J | Executive VP and CF ... | Option Exercise | M | 0.00 | 2,092 | 0 | 7,546 | |
Mar 02 2017 | IDPH | BIOGEN INC. | Clancy Paul J | Executive VP and CF ... | Option Exercise | M | 0.00 | 663 | 0 | 1,774 | |
Mar 02 2017 | IDPH | BIOGEN INC. | Clancy Paul J | Executive VP and CF ... | Option Exercise | J | 0.00 | 1,105 | 0 | 2,437 | |
Mar 02 2017 | IDPH | BIOGEN INC. | Clancy Paul J | Executive VP and CF ... | Option Exercise | J | 0.00 | 1,678 | 0 | 9,638 | |
Mar 02 2017 | IDPH | BIOGEN INC. | Clancy Paul J | Executive VP and CF ... | Option Exercise | J | 0.00 | 1,352 | 0 | 1,152 | |
Mar 02 2017 | IDPH | BIOGEN INC. | Clancy Paul J | Executive VP and CF ... | Payment of Exercise | F | 274.76 | 1,352 | 371,476 | 30,596 | 31.9 K to 30.6 K (-4.23 %) |
Mar 02 2017 | IDPH | BIOGEN INC. | Clancy Paul J | Executive VP and CF ... | Buy | M | 0.00 | 2,873 | 0 | 31,948 | 29.1 K to 31.9 K (+9.88 %) |
Mar 02 2017 | IDPH | BIOGEN INC. | Clancy Paul J | Executive VP and CF ... | Payment of Exercise | F | 274.76 | 543 | 149,195 | 29,075 | 29.6 K to 29.1 K (-1.83 %) |
Mar 02 2017 | IDPH | BIOGEN INC. | Clancy Paul J | Executive VP and CF ... | Buy | M | 0.00 | 1,152 | 0 | 29,618 | 28.5 K to 29.6 K (+4.05 %) |
Mar 02 2017 | IDPH | BIOGEN INC. | Clancy Paul J | Executive VP and CF ... | Payment of Exercise | F | 287.63 | 847 | 243,623 | 28,466 | 29.3 K to 28.5 K (-2.89 %) |
Mar 02 2017 | IDPH | BIOGEN INC. | Clancy Paul J | Executive VP and CF ... | Buy | M | 0.00 | 2,092 | 0 | 29,313 | 27.2 K to 29.3 K (+7.69 %) |
Mar 02 2017 | IDPH | BIOGEN INC. | Clancy Paul J | Executive VP and CF ... | Payment of Exercise | F | 284.75 | 312 | 88,842 | 27,221 | 27.5 K to 27.2 K (-1.13 %) |
Mar 02 2017 | IDPH | BIOGEN INC. | Clancy Paul J | Executive VP and CF ... | Buy | M | 0.00 | 663 | 0 | 27,533 | 26.9 K to 27.5 K (+2.47 %) |
Feb 17 2017 | IDPH | BIOGEN INC. | Clancy Paul J | Executive VP and CF ... | Option Exercise | A | 0.00 | 7,650 | 0 | 7,650 | |
Jun 23 2016 | AGIO | AGIOS PHARMACEUTIC ... | Clancy Paul J | Director | Option Exercise | A | 47.33 | 9,000 | 425,970 | 58,400 | |
May 31 2016 | INCY | INCYTE CORP | Clancy Paul J | Director | Option Exercise | A | 84.53 | 15,000 | 1,267,950 | 15,000 | |
Feb 25 2016 | IDPH | BIOGEN INC. | Clancy Paul J | Executive VP and CF ... | Option Exercise | J | 0.00 | 1,149 | 0 | 3,462 | |
Feb 25 2016 | IDPH | BIOGEN INC. | Clancy Paul J | Executive VP and CF ... | Option Exercise | M | 0.00 | 579 | 0 | 4,611 | |
Feb 25 2016 | IDPH | BIOGEN INC. | Clancy Paul J | Executive VP and CF ... | Payment of Exercise | F | 258.99 | 273 | 70,704 | 26,870 | 27.1 K to 26.9 K (-1.01 %) |
Feb 25 2016 | IDPH | BIOGEN INC. | Clancy Paul J | Executive VP and CF ... | Buy | M | 0.00 | 579 | 0 | 27,143 | 26.6 K to 27.1 K (+2.18 %) |
Feb 24 2016 | IDPH | BIOGEN INC. | Clancy Paul J | Executive VP and CF ... | Option Exercise | A | 0.00 | 11,060 | 0 | 11,060 | |
Feb 17 2016 | IDPH | BIOGEN INC. | Clancy Paul J | Executive VP and CF ... | Option Exercise | J | 0.00 | 1,394 | 0 | 2,448 | |
Feb 17 2016 | IDPH | BIOGEN INC. | Clancy Paul J | Executive VP and CF ... | Option Exercise | M | 0.00 | 2,807 | 0 | 2,808 | |
Feb 17 2016 | IDPH | BIOGEN INC. | Clancy Paul J | Executive VP and CF ... | Option Exercise | M | 0.00 | 1,052 | 0 | 3,842 | |
Feb 17 2016 | IDPH | BIOGEN INC. | Clancy Paul J | Executive VP and CF ... | Payment of Exercise | F | 247.22 | 1,204 | 297,653 | 26,564 | 27.8 K to 26.6 K (-4.34 %) |
Feb 17 2016 | IDPH | BIOGEN INC. | Clancy Paul J | Executive VP and CF ... | Buy | M | 0.00 | 2,807 | 0 | 27,768 | 25 K to 27.8 K (+11.25 %) |
Feb 17 2016 | IDPH | BIOGEN INC. | Clancy Paul J | Executive VP and CF ... | Payment of Exercise | F | 247.22 | 495 | 122,374 | 24,961 | 25.5 K to 25 K (-1.94 %) |
Feb 17 2016 | IDPH | BIOGEN INC. | Clancy Paul J | Executive VP and CF ... | Buy | M | 0.00 | 1,052 | 0 | 25,456 | 24.4 K to 25.5 K (+4.31 %) |
Feb 09 2016 | IDPH | BIOGEN INC. | Clancy Paul J | Executive VP and CF ... | Option Exercise | M | 0.00 | 3,194 | 0 | 0 | |
Feb 09 2016 | IDPH | BIOGEN INC. | Clancy Paul J | Executive VP and CF ... | Payment of Exercise | F | 250.77 | 1,047 | 262,556 | 24,404 | 25.5 K to 24.4 K (-4.11 %) |
Feb 09 2016 | IDPH | BIOGEN INC. | Clancy Paul J | Executive VP and CF ... | Buy | M | 0.00 | 3,194 | 0 | 25,451 | 22.3 K to 25.5 K (+14.35 %) |
Jun 25 2015 | AGIO | AGIOS PHARMACEUTIC ... | Clancy Paul J | Director | Option Exercise | A | 103.63 | 11,900 | 1,233,197 | 49,400 | |
May 27 2015 | INCY | INCYTE CORP | Clancy Paul J | Director | Option Exercise | A | 107.69 | 15,000 | 1,615,350 | 15,000 | |
Feb 25 2015 | IDPH | BIOGEN INC. | Clancy Paul J | Executive VP and CF ... | Option Exercise | A | 0.00 | 5,190 | 0 | 5,190 | |
Jun 03 2010 | IDPH | BIOGEN INC. | Clancy Paul J | Executive VP and CF ... | Payment of Exercise | F | 47.22 | 1,253 | 59,167 | 47,732 | 49 K to 47.7 K (-2.56 %) |
Feb 25 2010 | IDPH | BIOGEN INC. | Clancy Paul J | Executive VP and CF ... | Option Exercise | A | 0.00 | 17,123 | 0 | 17,123 | |
Feb 25 2010 | IDPH | BIOGEN INC. | Clancy Paul J | Executive VP and CF ... | Payment of Exercise | F | 55.29 | 1,066 | 58,939 | 48,985 | 50.1 K to 49 K (-2.13 %) |
Feb 25 2010 | IDPH | BIOGEN INC. | Clancy Paul J | Executive VP and CF ... | Payment of Exercise | F | 55.29 | 1,056 | 58,386 | 50,051 | 51.1 K to 50.1 K (-2.07 %) |
Feb 25 2010 | IDPH | BIOGEN INC. | Clancy Paul J | Executive VP and CF ... | Grant | A | 0.00 | 9,970 | 0 | 51,107 | 41.1 K to 51.1 K (+24.24 %) |
Feb 17 2010 | IDPH | BIOGEN INC. | Clancy Paul J | Executive VP and CF ... | Payment of Exercise | F | 55.21 | 1,661 | 91,704 | 41,137 | 42.8 K to 41.1 K (-3.88 %) |
Feb 17 2010 | IDPH | BIOGEN INC. | Clancy Paul J | Executive VP and CF ... | Payment of Exercise | F | 55.21 | 793 | 43,782 | 42,798 | 43.6 K to 42.8 K (-1.82 %) |
Sep 08 2009 | IDPH | BIOGEN INC. | Clancy Paul J | Executive VP and CF ... | Payment of Exercise | F | 51.01 | 1,114 | 56,825 | 43,591 | 44.7 K to 43.6 K (-2.49 %) |
Aug 03 2009 | IDPH | BIOGEN INC. | Clancy Paul J | Executive VP and CF ... | Payment of Exercise | F | 47.55 | 348 | 16,547 | 44,705 | 45.1 K to 44.7 K (-0.77 %) |
Aug 03 2009 | IDPH | BIOGEN INC. | Clancy Paul J | Executive VP and CF ... | Payment of Exercise | F | 47.55 | 835 | 39,704 | 45,053 | 45.9 K to 45.1 K (-1.82 %) |
Jun 03 2009 | IDPH | BIOGEN INC. | Clancy Paul J | Executive VP and CF ... | Payment of Exercise | F | 50.90 | 1,253 | 63,778 | 45,888 | 47.1 K to 45.9 K (-2.66 %) |
Feb 26 2009 | IDPH | BIOGEN INC. | Clancy Paul J | Executive VP and CF ... | Option Exercise | A | 49.65 | 26,785 | 1,329,875 | 26,785 | |
Feb 26 2009 | IDPH | BIOGEN INC. | Clancy Paul J | Executive VP and CF ... | Grant | A | 0.00 | 10,070 | 0 | 47,141 | 37.1 K to 47.1 K (+27.16 %) |
Feb 17 2009 | IDPH | BIOGEN INC. | Clancy Paul J | Executive VP and CF ... | Payment of Exercise | F | 52.61 | 1,661 | 87,385 | 35,410 | 37.1 K to 35.4 K (-4.48 %) |
Feb 17 2009 | IDPH | BIOGEN INC. | Clancy Paul J | Executive VP and CF ... | Payment of Exercise | F | 52.61 | 741 | 38,984 | 37,071 | 37.8 K to 37.1 K (-1.96 %) |
Feb 10 2009 | IDPH | BIOGEN INC. | Clancy Paul J | Executive VP and CF ... | Payment of Exercise | F | 52.48 | 529 | 27,762 | 39,473 | 40 K to 39.5 K (-1.32 %) |
Sep 23 2008 | IDPH | BIOGEN INC. | Clancy Paul J | Executive VP and CF ... | Sell | S | 50.00 | 1,553 | 77,650 | 40,002 | 41.6 K to 40 K (-3.74 %) |
Sep 08 2008 | IDPH | BIOGEN INC. | Clancy Paul J | Executive VP and CF ... | Payment of Exercise | F | 48.16 | 1,114 | 53,650 | 41,555 | 42.7 K to 41.6 K (-2.61 %) |
Aug 11 2008 | IDPH | BIOGEN INC. | Clancy Paul J | Executive VP and CF ... | Sell | S | 50.67 | 200 | 10,134 | 42,669 | 42.9 K to 42.7 K (-0.47 %) |
Aug 11 2008 | IDPH | BIOGEN INC. | Clancy Paul J | Executive VP and CF ... | Sell | S | 50.66 | 368 | 18,643 | 42,869 | 43.2 K to 42.9 K (-0.85 %) |
Aug 05 2008 | IDPH | BIOGEN INC. | Clancy Paul J | CFO | Grant | A | 0.00 | 6,000 | 0 | 43,237 | 37.2 K to 43.2 K (+16.11 %) |
Aug 05 2008 | IDPH | BIOGEN INC. | Clancy Paul J | CFO | Payment of Exercise | F | 50.01 | 265 | 13,253 | 37,237 | 37.5 K to 37.2 K (-0.71 %) |
Jul 02 2008 | IDPH | BIOGEN INC. | Clancy Paul J | CFO | Sell | S | 56.01 | 4,208 | 235,679 | 37,502 | 41.7 K to 37.5 K (-10.09 %) |
Jun 02 2008 | IDPH | BIOGEN INC. | Clancy Paul J | CFO | Payment of Exercise | F | 62.75 | 953 | 59,801 | 41,710 | 42.7 K to 41.7 K (-2.23 %) |
Feb 22 2008 | IDPH | BIOGEN INC. | Clancy Paul J | CFO | Sell | S | 60.89 | 100 | 6,089 | 42,663 | 42.8 K to 42.7 K (-0.23 %) |
Feb 22 2008 | IDPH | BIOGEN INC. | Clancy Paul J | CFO | Sell | S | 60.62 | 100 | 6,062 | 42,763 | 42.9 K to 42.8 K (-0.23 %) |
Feb 22 2008 | IDPH | BIOGEN INC. | Clancy Paul J | CFO | Sell | S | 60.47 | 100 | 6,047 | 42,863 | 43 K to 42.9 K (-0.23 %) |
Feb 22 2008 | IDPH | BIOGEN INC. | Clancy Paul J | CFO | Sell | S | 60.22 | 100 | 6,022 | 42,963 | 43.1 K to 43 K (-0.23 %) |
Feb 22 2008 | IDPH | BIOGEN INC. | Clancy Paul J | CFO | Sell | S | 60.20 | 483 | 29,077 | 43,063 | 43.5 K to 43.1 K (-1.11 %) |
Feb 22 2008 | IDPH | BIOGEN INC. | Clancy Paul J | CFO | Sell | S | 60.15 | 400 | 24,060 | 43,546 | 43.9 K to 43.5 K (-0.91 %) |
Feb 22 2008 | IDPH | BIOGEN INC. | Clancy Paul J | CFO | Sell | S | 60.14 | 100 | 6,014 | 43,946 | 44 K to 43.9 K (-0.23 %) |
Feb 22 2008 | IDPH | BIOGEN INC. | Clancy Paul J | CFO | Sell | S | 60.13 | 600 | 36,078 | 44,046 | 44.6 K to 44 K (-1.34 %) |
Feb 22 2008 | IDPH | BIOGEN INC. | Clancy Paul J | CFO | Sell | S | 60.07 | 100 | 6,007 | 44,646 | 44.7 K to 44.6 K (-0.22 %) |
Feb 22 2008 | IDPH | BIOGEN INC. | Clancy Paul J | CFO | Sell | S | 60.05 | 100 | 6,005 | 44,746 | 44.8 K to 44.7 K (-0.22 %) |
Feb 19 2008 | IDPH | BIOGEN INC. | Clancy Paul J | CFO | Payment of Exercise | F | 62.20 | 1,017 | 63,257 | 44,846 | 45.9 K to 44.8 K (-2.22 %) |
Feb 14 2008 | IDPH | BIOGEN INC. | Clancy Paul J | CFO | Option Exercise | A | 60.56 | 43,940 | 2,661,006 | 43,940 | |
Feb 14 2008 | IDPH | BIOGEN INC. | Clancy Paul J | CFO | Sell | S | 60.82 | 58 | 3,528 | 30,173 | 30.2 K to 30.2 K (-0.19 %) |
Feb 14 2008 | IDPH | BIOGEN INC. | Clancy Paul J | CFO | Sell | S | 60.88 | 200 | 12,176 | 30,231 | 30.4 K to 30.2 K (-0.66 %) |
Feb 14 2008 | IDPH | BIOGEN INC. | Clancy Paul J | CFO | Sell | S | 60.99 | 100 | 6,099 | 30,431 | 30.5 K to 30.4 K (-0.33 %) |
Feb 14 2008 | IDPH | BIOGEN INC. | Clancy Paul J | CFO | Sell | S | 60.76 | 200 | 12,152 | 30,531 | 30.7 K to 30.5 K (-0.65 %) |
Feb 14 2008 | IDPH | BIOGEN INC. | Clancy Paul J | CFO | Sell | S | 61.25 | 100 | 6,125 | 30,731 | 30.8 K to 30.7 K (-0.32 %) |
Feb 14 2008 | IDPH | BIOGEN INC. | Clancy Paul J | CFO | Sell | S | 61.29 | 100 | 6,129 | 30,831 | 30.9 K to 30.8 K (-0.32 %) |
Feb 14 2008 | IDPH | BIOGEN INC. | Clancy Paul J | CFO | Sell | S | 60.94 | 200 | 12,188 | 30,931 | 31.1 K to 30.9 K (-0.64 %) |
Feb 14 2008 | IDPH | BIOGEN INC. | Clancy Paul J | CFO | Grant | A | 0.00 | 15,690 | 0 | 45,863 | 30.2 K to 45.9 K (+52.00 %) |
Feb 14 2008 | IDPH | BIOGEN INC. | Clancy Paul J | CFO | Payment of Exercise | F | 60.56 | 742 | 44,936 | 31,131 | 31.9 K to 31.1 K (-2.33 %) |
Feb 07 2008 | IDPH | BIOGEN INC. | Clancy Paul J | CFO | Payment of Exercise | F | 60.52 | 522 | 31,591 | 31,873 | 32.4 K to 31.9 K (-1.61 %) |
Sep 05 2007 | IDPH | BIOGEN INC. | Clancy Paul J | CFO | Option Exercise | A | 63.55 | 20,000 | 1,271,000 | 20,000 | |
Sep 05 2007 | IDPH | BIOGEN INC. | Clancy Paul J | CFO | Grant | A | 0.00 | 8,000 | 0 | 32,395 | 24.4 K to 32.4 K (+32.79 %) |
Page: 1